Abstract
A US District Court has called into question the validity of patents directed to DNA sequences and diagnostic methods based on such sequences. If upheld on appeal, the District Court ruling will severely impair the ability of universities and the biotech industry to patent their inventions, raise capital and maintain share prices. Since the reasoning could equally be applied to novel drugs based on naturally occurring compounds, the decision should also be of concern to the pharmaceutical industry in general.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
